CAMBRIDGE, England, June 25 /PRNewswire/ -- O2h has initiated a networked approach towards being a full service discovery services company at the forefront of drug discovery research. O2h has established a new biology lab on-site in Ahmedabad, India offering physio-chemical and CYP450 assays.
O2h announces the first of its Biology Affiliate Partnership with Hypoxium Ltd. UK. Hypoxium has specialist capabilities in in vitro, cell-based oncology assays which will now be available in a seamless integration with the existing assays performed on-site by O2h.
Sunil Shah, CEO of O2h said "The focus of our biology strategy is to deliver seamless drug discovery via core centres of excellence. We are very happy to bring on board Hypoxium as an affiliate so O2h can now support its clients with oncology focused cell biology assays.
Dan Cowell, CEO of Hypoxium, said: "Working with O2h is an excellent fit with our strategy of supporting drug discovery research in a collaborative manner. It allows O2h clients access to focused cell biology via their existing project manager, yet retains transparent communication with the scientific team responsible for each area."
O2h is a 4+ year old discovery services company with project offices in Cambridge, UK and research labs in Ahmedabad, India. Indian operations provide a high level of discovery expertise while UK office provides project management support. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services lab-units and ADME. More details at http://www.o2h.com.
Based in Cambridge UK, Hypoxium was formed in October 2006 with the sole intention of providing comprehensive, high quality and affordable custom cell biology research services within the oncology therapeutic area. Hypoxium's goal is to provide scientifically driven and industry focused pre-clinical solutions, to assist in the development of novel therapies for oncology. Hypoxium can support projects from proof-of concept through to pre-clinical evaluation of new chemical entities. Since its formation, Hypoxium has attracted a wide range of clients and successfully delivered results that have significantly contributed to their discovery programs. More details at http://www.hypoxium.com.
O2h Contact: Ekta Ahuja Email: email@example.com Hypoxium Contact: Dan Cowell Email: firstname.lastname@example.org
|SOURCE O2h and Hypoxium|
Copyright©2009 PR Newswire.
All rights reserved